Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graeme Moyle

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
The Journal of Infectious Diseases|November 6, 2014
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled studyElchonon M Berkowitz, Graeme Moyle, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2018
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and CognitionEmilie R Elliot, Xinzhu Wang, Suveer Singh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 14, 2020
Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
AIDS Research and Therapy|January 29, 2013
NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trialsStephen Brown, David M Simpson, Graeme Moyle, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2009
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjectsGraeme Moyle, Marta Boffito, Carl Fletcher, et al.
Journal of the International AIDS Society|November 15, 2014
Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitorMartin Fisher, Cheryl McDonald, Graeme Moyle, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
The Journal of Infectious Diseases|November 6, 2014
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled studyElchonon M Berkowitz, Graeme Moyle, Hans-Jürgen Stellbrink, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 18, 2018
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and CognitionEmilie R Elliot, Xinzhu Wang, Suveer Singh, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 14, 2020
Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIVBranca Pereira, Maria Mazzitelli, Ana Milinkovic, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological responseAlan Winston, Nimesh Patel, David Back, et al.
Antimicrobial Agents and Chemotherapy|July 22, 2015
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake CessationLaura Dickinson, H Manisha Yapa, Akil Jackson, et al.
AIDS Research and Therapy|January 29, 2013
NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trialsStephen Brown, David M Simpson, Graeme Moyle, et al.
Antimicrobial Agents and Chemotherapy|February 4, 2009
Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjectsGraeme Moyle, Marta Boffito, Carl Fletcher, et al.
Journal of the International AIDS Society|November 15, 2014
Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitorMartin Fisher, Cheryl McDonald, Graeme Moyle, et al.
Pageof 12